Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Receives Nasdaq Delisting Warning; Has Until Sept. 27 to Raise Share Price Above $1

NEW YORK, April 5 (GenomeWeb News) - Transgenomic has until Sept. 27 to lift its shares above $1 or risk being delisted from the Nasdaq exchange, the company said in an SEC filing yesterday.


The news prompted shares in Transgenomic to tumble 13.46 percent, or $.07, to $.45 in mid-afternoon trading.


As GenomeWeb News reported this week, shares in Transgenomic have closed below $1 for 30 consecutive trading days, which is the Nasdaq's minimum price threshold for continued listing.


According to the SEC filing, Transgenomic received a letter from the exchange on March 31 stating that for "the last 30 days the bid price of [Transgenomic's] common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4450(a)(5).


"In accordance with Marketplace Rule 4450(e)(2), Registrant will be provided 180 calendar days, or until September 27, 2005, to regain compliance," according to the filing.


Transgenomic said it "has not determined an action or response to the notice as of the time of this filing."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.